Analyst Price Target is $45.71
▲ +34.53% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for InMode in the last 3 months. The average price target is $45.71, with a high forecast of $60.00 and a low forecast of $40.00. The average price target represents a 34.53% upside from the last price of $33.98.
Current Consensus is
The current consensus among 6 contributing investment analysts is to buy stock in InMode. This Buy consensus rating has held steady for over two years.
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.